BRPI0511571A - derivados de aminopiridina como agonistas de dopamina d3 seletivos - Google Patents
derivados de aminopiridina como agonistas de dopamina d3 seletivosInfo
- Publication number
- BRPI0511571A BRPI0511571A BRPI0511571-0A BRPI0511571A BRPI0511571A BR PI0511571 A BRPI0511571 A BR PI0511571A BR PI0511571 A BRPI0511571 A BR PI0511571A BR PI0511571 A BRPI0511571 A BR PI0511571A
- Authority
- BR
- Brazil
- Prior art keywords
- selective
- disorders
- agonists
- disorder
- sexual
- Prior art date
Links
- 150000003927 aminopyridines Chemical class 0.000 title abstract 2
- 229940052760 dopamine agonists Drugs 0.000 title abstract 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 3
- 208000021663 Female sexual arousal disease Diseases 0.000 abstract 2
- 206010057671 Female sexual dysfunction Diseases 0.000 abstract 2
- 206010024419 Libido decreased Diseases 0.000 abstract 2
- 206010057672 Male sexual dysfunction Diseases 0.000 abstract 2
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 2
- 208000017020 hypoactive sexual desire disease Diseases 0.000 abstract 2
- 206010002652 Anorgasmia Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 208000014840 female orgasmic disease Diseases 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 201000004197 inhibited female orgasm Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 206010036596 premature ejaculation Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
DERIVADOS DE AMINOPIRIDINA COMO AGONISTAS DE DOPAMINA D3 SELETIVOS A presente invenção provê compostos da fórmula (I) que são uma classe de agonistas de dopamina, mais particularmente uma classe de agonistas que são seletivos para D3 em relação a D2. Esses compostos são úteis para o tratamento e/ou prevenção de disfunção sexual, por exemplo, disfunção sexual feminina (FSD), em particular distúrbio de excitação sexual feminina (FSAD), distúrbio de desejo sexual hipoativo (HSDD; falta de interesse em sexo), distúrbio orgásmico feminino (FOD; incapacidade de atingir orgasmo); e disfunção sexual masculina, em particular disfunção erétil masculina (MED). Disfunção sexual masculina conforme aqui referido pretende incluir distúrbios ejaculatórios tal como ejaculação precoce, anorgasmia (incapacidade em atingir orgasmo) ou distúrbios de desejo tal como distúrbio de desejo sexual hipoativo (HSDD; falta de interesse em sexo). Esses compostos são também úteis no tratamento de distúrbios neuropsiquiátricos e distúrbios neurodegenerativos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0411891A GB0411891D0 (en) | 2004-05-27 | 2004-05-27 | New aminopyridine derivatives and their use as pharmaceuticals |
| GB0412463A GB0412463D0 (en) | 2004-06-03 | 2004-06-03 | New aminopyridine derivatives and their use as pharmaceuticals |
| PCT/IB2005/001554 WO2005115985A1 (en) | 2004-05-27 | 2005-05-17 | Aminopyridine derivatives as selective dopamine d3 agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0511571A true BRPI0511571A (pt) | 2008-01-02 |
Family
ID=34970000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0511571-0A BRPI0511571A (pt) | 2004-05-27 | 2005-05-17 | derivados de aminopiridina como agonistas de dopamina d3 seletivos |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1758862A1 (pt) |
| JP (1) | JP4198183B2 (pt) |
| AP (1) | AP2006003824A0 (pt) |
| AR (1) | AR049548A1 (pt) |
| AU (1) | AU2005247699A1 (pt) |
| BR (1) | BRPI0511571A (pt) |
| CA (1) | CA2567935C (pt) |
| EA (1) | EA200601982A1 (pt) |
| EC (1) | ECSP067029A (pt) |
| GT (1) | GT200500125A (pt) |
| IL (1) | IL179314A0 (pt) |
| MA (1) | MA28607B1 (pt) |
| MX (1) | MXPA06013786A (pt) |
| NL (1) | NL1029139C2 (pt) |
| NO (1) | NO20065326L (pt) |
| PA (1) | PA8635101A1 (pt) |
| PE (1) | PE20060366A1 (pt) |
| SV (1) | SV2005002129A (pt) |
| TW (1) | TW200609216A (pt) |
| UY (1) | UY28925A1 (pt) |
| WO (1) | WO2005115985A1 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0502509D0 (en) * | 2005-02-07 | 2005-03-16 | Pfizer Ltd | Novel salt form of a dopamine agonist |
| CA2752105C (en) * | 2009-02-13 | 2017-10-31 | Matthias Vennemann | Fused pyrimidines |
| EP2558437B1 (en) * | 2010-04-12 | 2015-08-05 | Supernus Pharmaceuticals, Inc. | Methods for producing viloxazine salts and novel polymorphs thereof |
| US9504949B2 (en) | 2011-06-30 | 2016-11-29 | Donaldson Company, Inc. | Air/oil separator assemblies; components; and methods |
| GB2543296A (en) * | 2015-10-13 | 2017-04-19 | Indivior Uk Ltd | Dopamine D3 receptor antagonists having a morpholine moiety |
| HRP20241015T1 (hr) | 2016-07-20 | 2024-11-08 | Novartis Ag | Derivati aminopiridina i njihova uporaba kao selektivnih alk-2 inhibitora |
| IL274868B2 (en) * | 2017-12-08 | 2024-06-01 | Boehringer Ingelheim Int | History of imidazopyridine and their use as medicine |
| US12479838B2 (en) * | 2019-04-12 | 2025-11-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof |
| MX2022006176A (es) | 2019-11-22 | 2022-08-17 | Incyte Corp | Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2. |
| PH12022553501A1 (en) | 2020-06-16 | 2024-04-22 | Incyte Corp | Alk2 inhibitors for the treatment of anemia |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5077290A (en) * | 1990-10-11 | 1991-12-31 | Merck & Co., Inc. | Morpholine derivatives compositions and use |
| GB0130219D0 (en) * | 2001-12-18 | 2002-02-06 | Pfizer Ltd | Compounds for the treatment of sexual dysfunction |
| NZ540505A (en) * | 2002-12-10 | 2007-02-23 | Pfizer | Morpholine derivatives for use as dopamine agonists in the treatment of I.A. sexual dysfunction |
-
2005
- 2005-05-17 CA CA002567935A patent/CA2567935C/en not_active Expired - Fee Related
- 2005-05-17 JP JP2007514200A patent/JP4198183B2/ja not_active Expired - Fee Related
- 2005-05-17 AU AU2005247699A patent/AU2005247699A1/en not_active Abandoned
- 2005-05-17 EA EA200601982A patent/EA200601982A1/ru unknown
- 2005-05-17 AP AP2006003824A patent/AP2006003824A0/xx unknown
- 2005-05-17 BR BRPI0511571-0A patent/BRPI0511571A/pt not_active Application Discontinuation
- 2005-05-17 MX MXPA06013786A patent/MXPA06013786A/es not_active Application Discontinuation
- 2005-05-17 WO PCT/IB2005/001554 patent/WO2005115985A1/en not_active Ceased
- 2005-05-17 EP EP05747191A patent/EP1758862A1/en not_active Withdrawn
- 2005-05-24 GT GT200500125A patent/GT200500125A/es unknown
- 2005-05-25 PE PE2005000583A patent/PE20060366A1/es not_active Application Discontinuation
- 2005-05-26 NL NL1029139A patent/NL1029139C2/nl not_active IP Right Cessation
- 2005-05-26 PA PA20058635101A patent/PA8635101A1/es unknown
- 2005-05-26 AR ARP050102169A patent/AR049548A1/es unknown
- 2005-05-26 UY UY28925A patent/UY28925A1/es not_active Application Discontinuation
- 2005-05-26 TW TW094117274A patent/TW200609216A/zh unknown
- 2005-05-27 SV SV2005002129A patent/SV2005002129A/es not_active Application Discontinuation
-
2006
- 2006-11-15 IL IL179314A patent/IL179314A0/en unknown
- 2006-11-20 NO NO20065326A patent/NO20065326L/no unknown
- 2006-11-27 MA MA29488A patent/MA28607B1/fr unknown
- 2006-11-27 EC EC2006007029A patent/ECSP067029A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY28925A1 (es) | 2005-12-30 |
| AU2005247699A1 (en) | 2005-12-08 |
| GT200500125A (es) | 2006-01-10 |
| NO20065326L (no) | 2006-12-19 |
| PA8635101A1 (es) | 2006-05-16 |
| JP4198183B2 (ja) | 2008-12-17 |
| WO2005115985A1 (en) | 2005-12-08 |
| JP2008500331A (ja) | 2008-01-10 |
| AP2006003824A0 (en) | 2006-12-31 |
| AR049548A1 (es) | 2006-08-16 |
| ECSP067029A (es) | 2006-12-29 |
| EP1758862A1 (en) | 2007-03-07 |
| IL179314A0 (en) | 2007-03-08 |
| CA2567935A1 (en) | 2005-12-08 |
| PE20060366A1 (es) | 2006-05-15 |
| TW200609216A (en) | 2006-03-16 |
| MA28607B1 (fr) | 2007-05-02 |
| MXPA06013786A (es) | 2007-01-25 |
| CA2567935C (en) | 2009-10-27 |
| NL1029139C2 (nl) | 2006-06-19 |
| SV2005002129A (es) | 2005-12-13 |
| EA200601982A1 (ru) | 2007-04-27 |
| NL1029139A1 (nl) | 2005-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20217265B (en) | Glp-1 receptor agonists and uses thereof | |
| PH12019550050A1 (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
| SG10201909545XA (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
| MX2023009483A (es) | Anticuerpos monoclonales para usarse para el tratamiento de sinucleinopatia. | |
| CL2017000864A1 (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| MY192717A (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
| MX2015012502A (es) | Inhibidores de proteina cinasa dependiente de adn. | |
| IN2014KN02601A (pt) | ||
| BRPI0511571A (pt) | derivados de aminopiridina como agonistas de dopamina d3 seletivos | |
| MX373786B (es) | Derivados de pirimidin-2,4-diamina para el tratamiento de cáncer. | |
| CO6430487A2 (es) | Anticuerpos anti-her | |
| PH12018502497A1 (en) | Adenosine derivatives for use in the treatment of cancer | |
| GB2503852A (en) | Compounds for the treatment of neuropsychiatric disorders | |
| PH12019501224A1 (en) | Compositions for treatment of polycystic kidney disease | |
| EA201391702A1 (ru) | Интраназальные тестостероновые составы с пониженной дозировкой в виде геля и их применение для лечения аноргазмии или гипоактивного расстройства сексуального желания | |
| TW200607500A (en) | New indazole and indolone derivatives and their use as pharmaceuticals | |
| PE20211268A1 (es) | Proceso para preparar el benzotiofen-2-il boronato | |
| DOP2005000095A (es) | Nuevos derivados de aminopiridina y su uso como farmacos | |
| MA44836A (fr) | Procédés de traitement du syndrome polykystique des reins | |
| DOP2005000093A (es) | Nuevos derivados de indazol e indolona y su uso como productos farmaceuticos | |
| TH75888A (th) | อนุพันธ์อะมิโนไพริดีนตัวใหม่และการใช้สารนั้นเป็นเภสัชภัณฑ์ | |
| TH75891A (th) | อนุพันธ์อินแดโซลและอินโดโลนตัวใหม่ และการใช้มันเป็นสารเชิงเภสัชวิทยา | |
| MX2016008272A (es) | Metodos para el tratamiento de mujeres con trastornos de deseo sexual hipoactivo (hsdd) con el tratamiento de combinacion bupropion y trazodona. | |
| EA201792070A1 (ru) | Средство для лечения дисфункции лобной доли | |
| EA201891690A1 (ru) | Агонист fxr, представляющий собой производное стероидов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |